Published in Blood Weekly, February 7th, 2002
"Treatment of patients with adult T cell leukemia-lymphoma (ATLL) using conventional chemotherapy has limited benefit because human T-cell leukemia virus type 1 (HTLV-1) cells are resistant to most apoptosis-inducing agents," with the recently discovered exception of arsenic trioxide, explained Renaud Mahieux and colleagues at the Pasteur Institute in Paris and the U.S. National Cancer Institute in Bethesda, Maryland.
Mahieux and coauthors determined...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.